Table 2.
Definitions of metabolic syndrome and adjusted ORs of associated microalbuminuria.
| WHO 1998 [38] | EGIR 1999 [49] | NCEP ATP III 2001 [39] | IDF 2005 [40] | AHA 2005 [2] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Essential criteria Definition of MetS |
IFG, IGT, or IR plus 2 of other 5 criteria |
Insulin in top 25% plus 2 of other 4 criteria |
Any 3 of 5 criteria listed below |
Increased waist plus any of 2 of other 4 criteria |
Any 3 of 5 criteria listed below |
|||||
| Abdominal obesity (men/women) |
Waist-to-hip ratio >0.9/0.85 BMI > 30 (kg/m2) |
Waist ≧ 94/80 | Waist > 90/80 | Men ≥94 cm (European) ≥90 cm (Chinese) ≥90 cm (South Asian) ≥85 cm (Japanese) |
Women ≥80 cm (European) ≥80 cm (Chinese) ≥80 cm (South Asian) ≥90 cm (Japanese) |
Waist ≧ 90/80 | ||||
| Triglycerides (nmol/L) |
≧1.7 or drug treatment for this lipid abnormality |
>2.0 or drug treatment for this lipid abnormality |
≧1.7 or drug treatment for this lipid abnormality |
≧1.7 or drug treatment for this lipid abnormality |
≧1.7 or drug treatment for this lipid abnormality |
|||||
| HDL cholesterol (nmol/L) (men/women) |
<0.9/1.0 or drug treatment for this lipid abnormality |
<1.0 or drug treatment for this lipid abnormality |
<1.0/1.3 or drug treatment for this lipid abnormality |
<1.0/1.3 or drug treatment for this lipid abnormality |
<1.0/1.3 or drug treatment for this lipid abnormality |
|||||
| Blood pressure (mmHg) |
More than 140/90 or drug treatment for hypertension |
More than 140/90 or drug treatment for hypertension |
More than 130/85 or drug treatment for hypertension |
More than 130/85 or drug treatment for hypertension |
More than 130/85 or drug treatment for hypertension |
|||||
| Fasting glucose (nmol/L) |
More than 6.1 HOMA-IR >2.53 |
More than 6.1 | More than 6.1 | More than 5.6 | More than 5.6 | |||||
| Urinary albumin excretion |
More than 30 mg/g creatinine |
— | — | — | — | |||||
| Adjusted ORs (95% CI) of microalbuminuria [41] |
Men 4.44*** (2.85–6.91) |
Women 4.16*** (2.57–6.73) |
Men 2.62*** (1.49–4.60) |
Women 1.80 (0.99–3.29) |
Men 1.99 (1.31–3.03) |
Women 2.21*** (1.47–3.32) |
Men 1.51 (0.97–2.35) |
Women 2.29*** (1.51–3.48) |
Men 1.64* (1.08–2.50) |
Women 2.26*** (1.52–3.38) |
World Health Organization (WHO), European Group for the Study of Insulin Resistance (EGIR), National Cholesterol Education Program (NCEP), Adult Treatment Panel III (ATP-III), International Diabetes Federation (IDF), American Heart Association and National Heart Lung and Blood Institute (AHA/NHLBI), Metabolic Syndrome (MetS); Body mass index (BMI); high-density lipoprotein (HDL); homeostasis model assessment of insulin resistance (HOMA-IR); insulin resistance (IR). Adjusted OR (95% CI) of microalbuminuria: a cross-sectional epidemiological study based on data from the Taichung Community Health Study [41]. *P < .05; **P < .01; ***P < .001.